OncoArendi Therapeutics (OAT) is an innovative biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for neoplastic and inflammatory diseases.
OncoArendi's business model is strictly focused on drug discovery and development, with its core strength in high quality medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas and prudent use of CROs.
A seasoned management team with several decades of relevant experience in drug discovery and development from large pharma, small biotech, technology-based startups, CROs and academic environments.
An attractive portfolio of projects focusing on novel biological targets with high potential market value ("first in class" drug candidates) in respiratory and immuno-oncology.
An established network of collaborators and an active participation in the forming Warsaw bio-tech-med cluster to fuel more opportunities. OncoArendi is interested in establishing new alliances and partnerships early in the drug development process to leverage its core competencies
OncoArendi Therapeutics was incepted in 2012. Following the Founders seed and in-kind contributions, OncoArendi Therapeutics closed an Angel and two investment rounds totalling about 34 million PLN (9 million USD, based on averaged variable exchange rate over time).
In addition OncoArendi has been able to significantly leverage the private capital raised with non-dilutive grants, with total funding exceeding 100 million PLN (almost 30 million USD, based on averaged variable exchange rate over time).
The total cumulative (private and public) funding should allow OncoArendi Therapeutics to progress four of its ongoing programs up to Phase II clinical trials and fill its pipeline with new, early stage exploratory programs.